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The aim of this work was to study the pathological processes underlying neurological dysfunctions
displayed by BALB/C mice induced with experimental antiphospholipid syndrome (APS), as we have
previously reported. Experimental APS was induced in female BALB/C mice by immunization with a
pathogenic monoclonal anticardiolipin (aCL) antibody, H-3 ðn ¼ 10Þ; or an irrelevant immunoglo-
bulin in controls ðn ¼ 10Þ: Mice immunized with H-3 developed clinical and neurological
manifestations of APS, including: embryo resorption, thrombocytopenia neurological defects and
behavioral disturbances. In mouse sera, the titer of various autoantibodies were elevated, including:
anti-phospholipids (aPLs), anti-b2 glycoprotein-I (b2GPI), anti-endothelial cell antibodies (AECA)
and low titer of anti-dsDNA antibodies. Five months after APS induction, mice were sacriﬁced and
brain tissue specimens were processed for hematoxylin and eosin (H&E), immunoﬂuorescence
staining and transmission electron microscopy (TEM). H&E staining of cortical tissue derived from
all APS mice revealed mild inﬂammation, localized mainly in the meninges. Prominent IgG deposits
in the large vessel walls and perivascular IgG leakage were observed by immunoﬂuorescence. No
large thrombi were observed in large vessels. However, EM evaluation of cerebral tissue revealed
pathological changes in the microvessels. Thrombotic occlusion of capillaries in combination with
mild inﬂammation was the main ﬁnding and may underlie the neurological defects displayed by mice
with APS.
Keywords: Antiphospholipid syndrome; Autoantibodies; Mouse; Neurological manifestations;
Thrombosis
Abbreviations: APS, antiphospholipid syndrome; SLE, systemic lupus erythematosus; CL, cardiolipin;
PLs, phospholipids; b2GPI, beta-2-glycoprotein-I; AECA, anti-endothelial cell antibodies; EC,
endothelial cells; HUVEC, Human umbilical vein endothelial cells; TEM, transmission electron
microscopy; H&E, hematoxylin and eosin
INTRODUCTION
The antiphospholipid syndrome (APS) is an autoimmune
disorder characterized by recurrent thrombotic (venous or
arterial) events, repeated spontaneous abortions, and
thrombocytopenia, in combination with persistently
elevated titers of anti-phospholipid antibodies (aPL) or
lupus anticoagulants (Hughes, 1993; Asherson et al.,
1996; Wilson et al., 1999). It appears as a primary
entity, or in the constellation of other autoimmune
diseases, mainly systemic lupus erythematosus (SLE)
(Asherson and Cervera, 1994; Asherson et al., 1996). A
wide spectrum of other clinical manifestations with a
multi-organ involvement has been reported in association
with APS (Hojnik et al., 1996; Ziporen et al., 1996; Levy
et al., 1997; Brey, 2000), including valvular heart disease,
dermal, renal and neurological dysfunctions. The neuro-
logical impairments reported in association with APS
(Brey, 2000) include: transient ischemic attacks (TIA’s)
and strokes in young people (Levine et al., 1990;
Ginsburg et al., 1992; Brey et al., 1993; Toubi et al.,
1995), amaurosis fugax (Digre et al., 1989), dementia
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(Inzelberg and Korczyn, 1989; Herranz et al., 1994;
Verrot et al., 1997) and chorea (Brey et al., 1993; Toubi
et al., 1995). However, the underlying mechanisms
responsible for the diverse neurological symptoms
associated with aPL are not fully understood.
Thrombotic events are believed to underlie many of
the clinical symptoms (Caudrado et al., 1997), with a
direct pathogenic role for thrombus formation attributed
to aPL (Kornberg et al., 1994; Pierangeli et al., 1995).
Yet, some neurological conditions, such as chorea,
migraine and diffuse cerebral atrophy, are not easily
explained by a solely thrombotic mechanism.
A direct interaction of aPL autoantibodies with
neuronal tissue is also plausible. Indeed, a number of
in vitro studies have shown a direct effect of aCL on
neuronal function (Sun et al., 1992; Liou et al., 1994;
Kent et al., 1997; Chapman et al., 1999). The aPL have
been shown to interfere with astrocytes proliferation
(Sun et al., 1992), to reduce GABA receptor-mediated
chloride currents in snail neurons (Liou et al., 1994), to
bind directly to neuronal tissue of different origins (Kent
et al., 1997) and to cause depolarization and
permeabilization of synaptoneurosomes (Chapman
et al., 1999).
Better understanding of these questions might derive
from experimental models of APS (Bakimer et al., 1992;
Ziporen et al., 1997). Neurological involvement in
experimental APS has been reported by us (Ziporen
et al., 1997; Katzav et al., 2001; Shrot et al., 2002) and
by others (Kier, 1990; Smith et al., 1990; Brey and
Teale, 1992; Hess et al., 1993; Aron et al., 1995). We
have demonstrated hyperactive behavior and other
neurological deﬁcits in BALB/c mice with experimental
primary APS (Ziporen et al., 1997). Cognitive impair-
ments and neurological symptoms have been demon-
strated also in MRL/lpr and NZB/NZW F1 lupus-prone
mice. Various degrees of inﬂammation and thrombosis
were the main pathological ﬁndings in the brains of
these mice (Kier, 1990; Smith et al., 1990; Brey and
Teale, 1992; Hess et al., 1993; Aron et al., 1995).
However, the speciﬁc association of similar ﬁndings
with aPLs has not been demonstrated in models of
primary APS.
The aim of this study was to assess the pathological
changes underlying neurological and behavioral
defects displayed by BALB/C mice with experimental
primary APS.
MATERIALS AND METHODS
Animals
Female BALB/c mice were obtained from the animal
house in the Tel-Aviv University Medical School. The
animals were raised under standard conditions, tempera-
ture 23 ^ 18C, 12:12h light–dark cycle with ad-libitum
access to food and water.
H-3 Monoclonal Antibody
H-3 is a natural human monoclonal IgM-aCL carrying a
pathogenic idiotype which is common in patients with
autoimmune diseases (Sutjita et al., 1989) and when
injected to naive BALB/c female mice induces primary
APS (Bakimer et al., 1992; Ziporen et al., 1997). The
antibody was afﬁnity puriﬁed from the supernatant of a
hybridoma cell line, kindly donated by Dr M. Sutjita, from
theFlindersMedical Center,SouthAustralia (Sutjitaetal.,
1989). Human IgM was used as control (Jackson
Immunoresearch Laboratories, West Grove, PA).
Endothelial Cell Cultures: Human Umbilical Vein
Endothelial Cells (HUVEC)
Human umbilical vein endothelial cells (HUVEC) were
isolated from umbilical cord veins as described previously
(Damianovich et al., 1996) and used for cyto-ELISA and
for FACS analysis to detect anti-endothelial cells
antibodies (AECA) in the mice serum.
Induction of Experimental APS in Mice by Active
Immunization with ACL (H-3)
BALB/c mice (8–10 weeks old females, weighing 25–
30g) were immunized intradermally in the hind
footpads with either 10mg H-3 ðn ¼ 10Þ; or normal
human IgM ðn ¼ 10Þ; emulsiﬁed in complete Freund’s
adjuvant (CFA, Difco Laboratories Inc., Detroit, MI). A
boost injection with 10mg of the H-3, or normal IgM in
phosphate buffer saline (PBS) was administered 3
weeks later.
Serological and Clinical Evaluation of the Mice
Mice were bled from the retro-orbital plexus at one-month
intervals. Blood cell counts were conducted using a single
optical cytometer (HC Plus Cell Control; Coulter
Electronics) for determination of thrombocytopenia.
Sera were separated and tested by ELISA for the presence
of autoantibodies.
ELISA
Serum samples were tested at 1:100 dilution for
anticardiolipin (aCL), anti-phosphatidylserine (aPS),
anti-phosphatidylinositol (aPl), anti-phosphatydilcholine
(aPC), anti-b2GPI, anti-dsDNA, anti-IgM and AECA.
Ninety six well polystyrene microtiter plates (Nunc,
Roskilde, Denmark) were coated with cardiolipin (CL),
phosphatidylserine (PS), phosphtidylinositol (PI), (or
empty wells) at 50mg/ml in ethanol, or with phospha-
tidylcholine (PC) in methanol/chloroform, then left open
at 48C until evaporation. For anti-human IgM detection,
microtiter plates were coated with 2mg/ml human IgM in
0.05M NaHCO3 buffer, pH 9.5, for overnight and washed
three times with 0.05%TBS-Tween.
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coated with poly-L-lysine at 50mg/ml in ddH2O for
30min at RT, washed £ 1 with TBS-Tween 0.1% and
£ 2 with TBS. Then, the wells were coated with calf
thymus DNA at 2.5mg/ml in TE for 2h at RT, washed
and neutralized with poly-L-glutamic acid at 50mg/ml in
TBS, for 1h at 378C.
Five percent bovine serum (BS) in tris buffer saline
(TBS) was used as blocking agent, and 2% BS in TBS, as
sample diluent. Washes were performed with TBS. The
antibody binding was quantitated using alkaline phospha-
tase-conjugated goat anti-mouse IgG or IgM (Jackson
Immunoresearch Laboratories, West Grove, PA), followed
by p-nitrophenylphosphate substrate. Optical density
(OD) was read at 405nm.
For the detection of antibodies to b2 glycoprotein-I
(b2GPI), microtiter plates were coated with 2.5mg/ml
puriﬁed human b2GPI (kindly donated by Dr A. Tincani,
Brescia, Italy) in 0.05M NaHCO3, pH-9.5 for 16–18h at
48C, followed by threewashes with PBS-0.05% Tween 20.
For blocking and sample dilution, 1% BSA-PBS-0.05%
Tween 20 was employed.
Anti-endothelial Cell Activity
Anti-endothelial cell activity in the animal sera was
measured in cyto-ELISA with unﬁxed HUVEC, accord-
ing to a previously described protocol (Damianovich
et al., 1996) in microtiter plates coated with conﬂuent
HUVEC endothelial cells. Brieﬂy, HUVEC cells were
seeded in gelatin coated 96-well microtiter plates
(Nunclon) at 2.5 £ 10
4 cells/well, and were allowed to
grow to conﬂuence for 1 or 2 days. Cells were washed
with Hank’s balanced salt solution (HBSS) and
incubated with a blocking buffer (HBSS/0.5% BSA)
for 30min at 378C to prevent non-speciﬁc binding. After
an additional wash cells were exposed to the tested sera
or control antibody diluted in HBSS/10% FCS (dilution
1:25–1:200 of serum) for 60min at room temperature.
Cells were washed again and incubated with a second
antibody, alkaline phosphatase-conjugated goat anti-
mouse IgG (Jackson Immuno Research Laboratory)
followed by p-nitrophenyl phosphate disodium (pNPP,
Sigma, St. Louis, MO) as a substrate. The OD was
read at 405nm by ELISA plate-reader (EAR 400 AT,
SLT-Labinstruments, Austria).
Flow Cytometric (FACS) Analysis of Mouse Serum
Binding to HUVEC
To detect AECA antibodies, serum pools of APS mice or
controls were assessed for binding to EC by FACS.
HUVEC cells (5 £ 10
5) in PBS-BSA 2% were incubated
with the mice pooled serum in 1:25 dilution (total volume
100ml) for 45min in 48C. The cells were washed twice in
PBS-BSA 2% and incubated with FITC-conjugated goat
anti-mouse IgG (Sigma) for 30min in 48C in the dark.
After 3 washes with washing buffer, the cells were ﬁltered
by a nylon-mesh ﬁlter and counted in a ﬂow cytometer
(Coulter, Hialeah, FL) equipped with a 500mW argon
laser and a helium–neon laser; 10
5 cells were tested in
each experiment. The percentage of cells stained was
determined.
Histological and Immunohistochemical Evaluation of
Brain Tissue Specimens
Perfusion and Tissue Preparation
Mice were deeply anaesthetized with sodium pentobarbi-
tone (Nembutal, Abbot, France), 50mg/kg body weight,
intra-peritoneal. A transcardiac perfusion was conducted
with 100ml physiologic, followed by a 10ml mixture of
1% paraformaldehyde and 10ml of 1.25% glutaraldehyde
in PBS. A specimen from the frontal cortex of each brain
was immersed in 2.5% glutaraldehyde for evaluation by
electron microscopy (EM). One hemisphere of each brain
was snap frozen in liquid nitrogen for immunoﬂuores-
cence study, and the other hemisphere was dispersed in
4% formaldehyde buffer for hematoxylin and eosin
(H&E) staining.
Immunoﬂuorescence Studies for the Detection of
Mouse IgG Deposits
Frozen brain tissue specimens derived from 10 APS mice
and 10 control mice were transversely cut into 10mm
thick sections and placed on poly-L-lysine coated slides.
Sections were stained with H&E and evaluated by direct
immunoﬂourescence, as described previously (Hojnik
et al., 1996). Brieﬂy, slides were dried under airstream
for 45min, ﬁxed in acetone for 5min at 2208C, and
rinsed three times for 5min in BSA-TBS-Tween. FITC-
conjugated primary antibody goat anti-mouse IgG
(Sigma), or FITC-conjugated normal goat IgG as control,
diluted in TBS, were applied for 30min at room
temperature (RT). The slides were rinsed three times for
5min in BSA-TBS-Tween, stained with Evans blue,
transferred to 95% ethanol for 2min, dried and mounted
with Entellan (Merck, Darmstadt, Germany), and
examined under a ﬂuorescence microscope (Olympus
Vanox AH3).
Transmission Electron Microscopy (TEM)
Brain samples from APS and control mice were processed
for TEM. Specimens (2 £ 2mm
3) of brain tissue were
ﬁxed in 2.5% glutaraldehyde in 0.1M cacodylate buffer
(pH 7.4) for 1h at RT. After several washings with the
same buffer, the tissues were post-ﬁxed with 2% OsO4 in
cacodylate buffer for 2h, washed, and dehydrated in a
graded ethanol solutions (30, 50, 75, 96, 100%) at RT. The
specimens were transferred to propylene oxide and
subsequently embedded in Epon embedding mixture
(Bio-Rad) at 55–658C for 3 days in a ﬂat mold. Thin
sections of 60mm were obtained with a Reichert ultra
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staining with lead citrate and examined with Joel-JEM
1200 EX II.
RESULTS
Serological Markers and In Vivo Assessment of Mice
Mice were evaluated for clinical and serological
manifestations of APS (Ziporen et al., 1997). As
previously published (Bakimer et al., 1992; Ziporen
et al., 1997), all the mice that had been immunized with
H-3 antibody demonstrated elevated titers of circulating
aPLs, including anti-CL, anti-PS and anti-PE antibodies,
anti-b2GPI antibodies, AECA, and anti-dsDNA, measured
by speciﬁc ELISA assays (Bakimer et al., 1992; Ziporen
et al., 1997). Control mice developed only anti-human
IgM (hIgM). Results of antibody levels at the time point
the mice were sacriﬁced, 5 months post immunization
with aCL, are summarized in Table I. Other manifes-
tations of APS were also found. Thrombocytopenia was
detected in the APS mice (Bakimer et al., 1992; Ziporen
et al., 1997). Number of platelets (average no. ^ SD) was
653 ^ 179 £ 10
3/m in APS mice, compared to
1076 ^ 217 £ 10
3/ml in the control mice, p , 0:05:
Fetuses resorption were measured, as previously described
(Bakimer et al., 1992; Ziporen et al., 1997), 12/32
resorptions were detected in APS mice, compared to 5/30
in the controls, p , 0:05: Behavioral and neurological
tests were conducted on all the mice, demonstrating
behavioral changes in the APS mice including hyperactive
behavior, defected performance of neurological reﬂexes
and motor incoordination, as previously described
(Ziporen et al., 1997).
Flow Cytometric Analysis Findings
To assess speciﬁc binding activity to endothelial cells
(EC), in addition to ELISA test, we performed ﬂow
cytometric analysis with HUVEC cells. Pooled serum
from 10 APS mice was found to bind 89% of HUVEC
cells tested (Fig. 1A), compared to 27% binding activity of
pooled sera from 10 control mice, as shown in Fig. 1B.
These results indicate that a speciﬁc binding reactivity to
TABLE I Antibodies level (average ^ SD) in the serum of APS mice and controls, as tested in ELISA (1:100 dilution), 5 months after the induction of
APS
Autoantibodies level in mouse sera (O.D.405)
Mouse group CL PS PI PC AECA dsDNA b2GPI HigM
APS 1.3 ^ 0.2 1.4 ^ 0.15 1.2 ^ 0.19 0.3 ^ 0.04 1.05 ^ 0.18 0.35 ^ 0.05 1.2 ^ 0.23 1.1 ^ 0.09
Control 0.13 ^ 0.02 0.2 ^ 0.025 0.1 ^ 0.02 0.15 ^ 0.01 0.15 ^ 0.03 0.12 ^ 0.02 0.25 ^ 0.03 1.15 ^ 0.02
CL: cardiolipin, PS: phosphatidylserine, PI: phosphatidylinositol, PC: phosphatidylcholine, AECA: anti-endothelial cell antibodies, dsDNA: double stranded DNA, b2GPI:
b2-glycoprotein-I, HIgM: human IgM antibodies.
FIGURE 1 Cytoﬂuorimetric evaluation of HUVEC endothelial cells
binding activity in APS mice (A) and control (B) serum (1:25 dilution of
pooled sera). Fluorescenceintensity (FITC)is displayed on the horizontal
axis and relative cell number on the vertical axis. (C) horizontal lines
indicate ﬂuorescent-positive cells stained with FITC-conjugated anti-
mouse IgG. Prominent positive binding activity of HUVEC cells (89%)
was found in serum of APS mice immunized with H-3 aCL antibody (a),
control mice serum (b) show limited binding activity of HUVEC cells
(27%).
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controls. These are either speciﬁc AECA that bind EC
(Bordron et al., 1998), or are aPL antibodies that
crossreact with ECs through b2GPI attached to EC (Del
Papa et al., 1995).
Pathological Findings
Histological and Immunoﬂuorescence Findings
H&E Staining
To observe gross pathological changes in cortical
specimens, H&E staining was performed on specimens
derived from the cortex of APS and control mice. Mild
inﬂammatory reactions were observed in 4 out of 10
cortical specimens of APS mice. Mononuclear inﬁltrates
were demonstrated in the meninges and subependymal
areas. In cortical specimens derived from control mice no
such inﬁltrates were discerned (Fig. 2A, B). By this
staining, no thrombus was observed in the brain
tissue specimens.
Immunofluorescence Staining
To show immune reactants deposited in the cerebral
tissue, immunoﬂuorescence staining was performed using
FITC-conjugatedanti-mouseIgG.InAPSmice,prominent
deposits of mouse IgG were shown in large and small
cerebral blood vessel walls along the endothelial lining
(Fig. 3A, B). Mild perivascular leakage of IgG was
also observed in the vicinity of affected blood vessels
(Fig. 3A, B). No such staining was observed in the control
mice brain.
FIGURE 2 H&E staining of a representative brain specimen derived from APS mouse immunized with H-3- monoclonal aCL. (A) Subependymal
inﬁltration of mononuclear cells is observed (arrow). (B) Inﬁltration of mononuclear cells is also seen in the meninges. (A,B) Original magniﬁcation,
£ 200.
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Toanalyze further the changesin the cortical tissue ofAPS
mice, TEM examination was conducted. Vasculopathy of
the cortical vessels was found in specimens derived from 4
out of 10 APS mice immunized with H-3 aCL (Ziporen
etal.,1997).IncorticalspecimensofAPSmice, upto35%
of capillaries shown in the tested ﬁeld were found
contracted, occluded by microthrombi and/or swollen
EC, compared to 5% contracted capillaries in the control
specimens, correlating with signiﬁcant neurological and
behavioral dysfunction, as previously reported (Ziporen
et al., 1997). As shown in Fig. 4, in the brain of APS mice
the capillaries were found contracted and occluded by
swollen EC leading to the formation of slit-like lumens
(Fig. 4A, B), compared to wide-open lumens in most of
control vessels. Aggregation of activated platelets with
cytoplasmic microvesicles and the formation of platelet
microthrombi were also observed in the capillaries of APS
specimens (Fig. 4C). Activated macrophages were shown
in the vicinity of occluded vessels (Fig. 4D). Extravasated
red blood cells were seen (Fig. 4E) in areas in which the
parenchyma next to the occluded capillaries showed
ischemic damage (Fig. 4F).
DISCUSSION
An experimental model for APS has been previously
established in our laboratory (Bakimer et al., 1992;
FIGURE 3 Immunoﬂuorescence staining of a representative brain tissue specimen from mouse immunized with aCL (H-3). Prominent staining of IgG
deposits is shown in the walls and endothelial lining of large vessels (A), as well as of smaller blood vessels (B). No such staining was seen in brain
specimens of the controls.
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with monoclonal aCL, carrying a pathogenic idiotype
(H-3). The mice developed several clinical manifes-
tations characteristic of the human disorder, such as
thrombocytopenia, fetal loss and elevated levels of
autoantibodies, including aPL, AECA and anti-b2GPI
antibodies (Bakimer et al., 1992; Ziporen et al., 1997).
Recently, we have shown that neurological dysfunction
and hyperactive behavior are also associated with
experimental APS, supporting the concept that neuro-
logical involvement is one of the manifestations of
APS1, 2, 8–10).
The mechanisms underlying neurological manifes-
tations in patients with APS are not yet fully understood.
Unraveling the type of pathology associated with
neurological disease in APS is crucial for choosing the
appropriate form of drug treatment for the patients.
Since neuropathologic studies in patients with APS and
neurological disturbances are limited (Coull et al., 1987;
Leach et al., 1989; Lie, 1989; Levine et al., 1990;
Westerman et al., 1992; Hugston et al., 1993; Lie, 1994),
we aimed to investigate this unresolved question utilizing
our experimental model for primary APS in mice.
Some evidence exists in the literature regarding
histopathological processes associated with experimen-
tal APS that is secondary to lupus in lupus-prone mice
(Kier, 1990; Smith et al., 1990; Brey and Teale, 1992;
Hess et al., 1993; Aron et al., 1995), including the
MRL/lpr, its congenic strain MRLþþ mice immunized
with b2GPI (Smith et al., 1990; Brey and Teale, 1992;
Hess et al., 1993; Aron et al., 1995), and NZB/NZW
F1 mice (Kier, 1990). In these mice neurological
defects and cognitive impairment correlated with the
ﬁnding of perivascular lymphocytic inﬁltrates in the
choroid plexus, or around cerebral and hippocampal
blood vessels and occlusive vasculopathy (Kier, 1990;
Smith et al., 1990; Brey and Teale, 1992; Hess et al.,
1993; Aron et al., 1995). However, the correlation with
aCL was not elucidated in these mice models of
secondary APS.
FIGURE 4 Transmission electron micrographs of representative specimens derived from the frontal brain cortex of BALB/c female mice immunized
with monoclonal pathogenic aCL(H-3), or controls. (A) A capillary in a representative brain specimen derived from a control mouse is shown. Note the
wide open lumen (L) surrounded by an endothelial cell (arrow) £ 6000. (B) A brain specimen derived from the cortex of APS mice showing a capillary
with an occluded lumen (arrow) surrounded by swollen endothelial cells, leading to the formation of a slit-like lumen. Note the zinkling of basement
membrane. (arrowhead). £ 12000. (C) A capillary containing an aggregate of platelets. Note inside the platelets granules (arrows), vesicles and
pseudopodia-like processes (arrowhead) £ 7500. (D) Agglutination of platelets forming a thrombus (arrow). The platelet membranes are preserved and
adhere to the endothelial cell. An activated macrophage (M) is discerned £ 5000. (E) extravasation of red blood cells (arrowheads) near occluded vessel
(arrow) and (F) damaged tissue (arrow) near an occluded capillary (arrowhead) ( £ 4000).
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assessment to brain tissue of naive BALB/C mice, not
genetically prone to develop an autoimmune disease, that
develop primary APS and neurological defects upon
induction with pathogenic idiotype (Bakimer et al., 1992;
Ziporen et al., 1997).
Experimental APS was generated in female BALB/C
mice that developed elevated levels of autoantibodies,
including aPLs, anti-b2GPI and AECA antibodies and low
levels of a dsDNA, as tested by ELISA (Table I).
Prominent binding of mice serum to HUVEC endothelial
cells was further conﬁrmed by FACS analysis (Fig. 1).
Clinical manifestations of APS were conﬁrmed, as
previously reported, and signiﬁcant neurological defects
were demonstrated including hyperactive behavior,
impaired neurological reﬂexes, and motor incoordination
(Ziporen et al., 1997).
The neurological deﬁcits displayed by APS mice were
found related mainly to the cortical level (Ziporen et al.,
1997). Therefore, we focused our attention on pathologi-
cal changes in the cortex of APS, compared to control
mice by a series of histopathological and ultrastructural
analyses.
H&E staining of cortical specimens derived from APS
mice revealed mainly mild inﬂammation, shown as small
inﬁltrates of lymphocytes localized in the meninges and in
subependymal areas (Fig. 2A, B). No wall thickening in
the capillaries was evident, arguing against the possibility
of classical vasculitis in the brain vessels associated with
experimental APS (Lie, 1989, 1994).
Immunoﬂuorescence staining of these specimens for
mouse IgG revealed prominent immunoglobulin deposits
in the EC lining of blood vessels, in contrast to the control
mice specimens (Fig. 3A, B). In addition, we observed
possible leakage of IgG into the adjacent brain tissue
(Fig. 3A), similar to the reported perivascular deposits of
IgG in the brains of MRL/lpr mice (Vogelweid et al.,
1991). Immune deposits in blood vessels may account for
EC damage occurring in these mice, leading to a
procoagulant state characteristic of APS. Moreover,
once the endothelial layer has been damaged, blood
components might have access to the brain tissue and
affect neural tissue. Indeed, in in vitro studies (Kent et al.,
1997) aPL antibodies react directly with different epitopes
in the cerebral tissue and interfere with functional
properties of the neurons (Sun et al., 1992; Liou et al.,
1994; Kent et al., 1997; Chapman et al., 1999). This
property attributed to aPL may explain the neurological
symptoms associated with APS which are not explicable
by a thrombotic process.
Our ultrastructural studies revealed signiﬁcant vasculo-
pathy in the cerebral capillaries of APS mice that
correlated with neurological dysfunction (Ziporen et al.,
1997). Many microvessels were found occluded by
platelet microthrombi (Fig. 4) and the neuronal tissue
adjacent to these vessels was found damaged. Activated
platelets were evident as aggregates in the cerebral
capillaries. The same phenomenon is seen in patients with
APS associated with thrombocytopenia and are a
prerequisite for vascular thrombosis in the pathogenesis
of haemostatic disorders in APS (Elison et al., 1995;
Silver et al., 1995; Fanelli et al., 1997)
Thrombotic changes in the microvasculature in
combination with leakage of aPL to the neuronal tissue
and mild inﬂammation in the meninges were found as the
main pathological changes in APS mice. These changes
may account for the hyperactivity and other neurological
defects observed in these animals (Ziporen et al., 1997).
Diverse autoimmune pathways, in which aPL, AECA or
anti-b2GPI antibodies are probably involved, damage the
neurons (Del Papa et al., 1995; Simantov et al., 1995;
Roubey and Hoffman, 1997; Bordron et al., 1998). The
autoantibodies may interfere in haemostasis leading to the
occlusion of microvessels, or bind directly to the neurons.
These results are in accordance with ﬁnding in autopsies
of APS patients, in whom the pathologic process of aPL-
associated neurologic disease resembles a non-vasculitic,
mild inﬂammatory thrombosis of small vessels, in which
the endothelial lining of small vessels is affected causing
multiple micro-infarcts in the cortex (Coull et al., 1987;
Leach et al., 1989; Lie, 1989; Westerman et al., 1992;
Hugston et al., 1993; Lie, 1994)
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